摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

二甲基-2-(2-硝基-4-三氟甲基苯基)丙二酸 | 290825-52-4

中文名称
二甲基-2-(2-硝基-4-三氟甲基苯基)丙二酸
中文别名
2-(2-硝基-4-三氟甲基苯基)丙二酸二甲酯
英文名称
dimethyl 2-(2-nitro-4-trifluoromethylphenyl)malonate
英文别名
2-(2-nitro-4-trifluoromethyl-phenyl)-malonic acid dimethyl ester;2-(2-nitro-4-trifluoromethylphenyl)-malonic Acid dimethyl ester;dimethyl 2-(2-nitro4-trifluoromethylphenyl)malonate;1,3-Dimethyl 2-[2-nitro-4-(trifluoromethyl)phenyl]propanedioate;dimethyl 2-[2-nitro-4-(trifluoromethyl)phenyl]propanedioate
二甲基-2-(2-硝基-4-三氟甲基苯基)丙二酸化学式
CAS
290825-52-4
化学式
C12H10F3NO6
mdl
MFCD03617804
分子量
321.21
InChiKey
MBAQGFLNQDHQCE-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    57-58°

计算性质

  • 辛醇/水分配系数(LogP):
    2.5
  • 重原子数:
    22
  • 可旋转键数:
    5
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.333
  • 拓扑面积:
    98.4
  • 氢给体数:
    0
  • 氢受体数:
    9

安全信息

  • 危险等级:
    IRRITANT
  • 危险品标志:
    Xi
  • 海关编码:
    2917399090
  • 危险性防范说明:
    P261,P280,P301+P312,P302+P352,P305+P351+P338
  • 危险性描述:
    H302,H315,H319,H335

SDS

SDS:f9a7fb7e494c65e16a8b6721da41eff9
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: Dimethyl 2-(2-nitro-4-trifluoromethylphenyl)malonate
Synonyms: Dimethyl 2-(2-nitro-4-(trifluoromethyl)phenyl)malonate

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: Dimethyl 2-(2-nitro-4-trifluoromethylphenyl)malonate
CAS number: 290825-52-4

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C12H10F3NO6
Molecular weight: 321.2

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen fluoride.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • 3-heteroarylidene-2-indolinone protein kinase inhibitors
    申请人:Sugen, Inc.
    公开号:US06486185B1
    公开(公告)日:2002-11-26
    The present invention relates to novel 3-heteroarylidene-2-indolinone compounds and physiologically acceptable salts thereof which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.
    本发明涉及新颖的3-杂环亚烯基-2-吲哚酮化合物及其生理上可接受的盐,这些化合物调节蛋白激酶的活性,因此预计在预防和治疗蛋白激酶相关的细胞疾病,如癌症方面具有用处。
  • Formulations for pharmaceutical agents ionizable as free acids or free bases
    申请人:Shenoy Narmada
    公开号:US06878733B1
    公开(公告)日:2005-04-12
    The present invention features formulations of indolinones which compounds are ionizable as free acids or free bases. The formulation is suitable for parenteral or oral administration, wherein the formulation comprises an ionizable substituted indolinone, and a pharmaceutically acceptable carrier therefor. The term “ionizable substituted indolinone” includes pyrrole substituted 2-indolinones which, in addition to being otherwise optionally substituted on both the pyrrole and 2-indolinone portions of the compound, are necessarily substituted on the pyrrole moiety with one or more hydrocarbon chains which themselves are substituted with at least one polar group. The formulations and the compounds themselves are useful for the treatment of protein kinase related disorders as discussed herein.
    本发明涉及吲哚酮的配方,这些化合物作为游离酸或游离碱是可离子化的。该配方适用于静脉或口服给药,其中配方包括可离子化的取代吲哚酮和其药用可接受载体。术语“可离子化的取代吲哚酮”包括吡咯取代的2-吲哚酮,除了在化合物的吡咯和2-吲哚酮部分上可选择地被取代外,必须在吡咯基上用一个或多个烃链取代,这些烃链本身被至少一个极性基团取代。如本文所述,这些配方和化合物本身对于治疗蛋白激酶相关疾病是有用的。
  • 3-(cycloalkanoheteroarylidenyl)-2-indolinone protein tyrosine kinase inhibitors
    申请人:Sugen, Inc.
    公开号:US06350754B2
    公开(公告)日:2002-02-26
    The present invention relates to novel 3-(cycloalkano-heteroarylidenyl)-2-indolinone compounds and physiologically acceptable salts and prodrugs thereof which are expected to modulate the activity of protein tyrosine kinases and therefore to be useful in the prevention and treatment of protein tyrosine kinase related cellular disorders such as cancer.
    本发明涉及新颖的3-(环烷基-杂环芳基亚亚甲基)-2-吲哚酮化合物及其生理上可接受的盐和前药,预计这些化合物可以调节蛋白酪氨酸激酶的活性,因此在预防和治疗蛋白酪氨酸激酶相关的细胞疾病,如癌症方面具有用处。
  • 3-(Piperazinylbenzylidenyl)-2-indolinone compounds and derivatives as protein tyrosine kinase inhibitors
    申请人:SUGEN, Inc.
    公开号:US20030069421A1
    公开(公告)日:2003-04-10
    The present invention relates to novel 3-(piperazinyl-benylidenyl)-2-indolinone compounds and derivatives and physiologically acceptable salts thereof which are expected to modulate the activity of protein tyrosine kinases and therefore to be useful in the prevention and treatment of protein tyrosine kinase related cellular disorders such as cancer.
    本发明涉及新颖的3-(哌嗪基苄亚基)-2-吲哚酮化合物及其衍生物和生理上可接受的盐,预计这些化合物可以调节蛋白酪氨酸激酶的活性,因此在预防和治疗蛋白酪氨酸激酶相关的细胞疾病,如癌症方面具有用处。
  • 3-(cycloalkanoheteroarylidenyl)-2- indolinone protein tyrosine kinase
    申请人:Sugen, Inc.
    公开号:US06051593A1
    公开(公告)日:2000-04-18
    The present invention relates to novel 3-(cycloalkanoheteroarylidenyl)-2-indolinone compounds and physiologically acceptable salts and prodrugs thereof which are expected to modulate the activity of protein tyrosine kinases and therefore to be useful in the prevention and treatment of protein tyrosine kinase related cellular disorders such as cancer.
    本发明涉及新颖的3-(环烷基杂环芳基亚亚基)-2-吲哚酮化合物及其生理上可接受的盐和前药,预计能调节蛋白酪氨酸激酶的活性,因此在预防和治疗蛋白酪氨酸激酶相关的细胞疾病如癌症方面具有用处。
查看更多

同类化合物

(5β,6α,8α,10α,13α)-6-羟基-15-氧代黄-9(11),16-二烯-18-油酸 (3S,3aR,8aR)-3,8a-二羟基-5-异丙基-3,8-二甲基-2,3,3a,4,5,8a-六氢-1H-天青-6-酮 (2Z)-2-(羟甲基)丁-2-烯酸乙酯 (2S,4aR,6aR,7R,9S,10aS,10bR)-甲基9-(苯甲酰氧基)-2-(呋喃-3-基)-十二烷基-6a,10b-二甲基-4,10-dioxo-1H-苯并[f]异亚甲基-7-羧酸盐 (+)顺式,反式-脱落酸-d6 龙舌兰皂苷乙酯 龙脑香醇酮 龙脑烯醛 龙脑7-O-[Β-D-呋喃芹菜糖基-(1→6)]-Β-D-吡喃葡萄糖苷 龙牙楤木皂甙VII 龙吉甙元 齿孔醇 齐墩果醛 齐墩果酸苄酯 齐墩果酸甲酯 齐墩果酸乙酯 齐墩果酸3-O-alpha-L-吡喃鼠李糖基(1-3)-beta-D-吡喃木糖基(1-3)-alpha-L-吡喃鼠李糖基(1-2)-alpha-L-阿拉伯糖吡喃糖苷 齐墩果酸 beta-D-葡萄糖酯 齐墩果酸 beta-D-吡喃葡萄糖基酯 齐墩果酸 3-乙酸酯 齐墩果酸 3-O-beta-D-葡吡喃糖基 (1→2)-alpha-L-吡喃阿拉伯糖苷 齐墩果酸 齐墩果-12-烯-3b,6b-二醇 齐墩果-12-烯-3,24-二醇 齐墩果-12-烯-3,21,23-三醇,(3b,4b,21a)-(9CI) 齐墩果-12-烯-3,11-二酮 齐墩果-12-烯-2α,3β,28-三醇 齐墩果-12-烯-29-酸,3,22-二羟基-11-羰基-,g-内酯,(3b,20b,22b)- 齐墩果-12-烯-28-酸,3-[(6-脱氧-4-O-b-D-吡喃木糖基-a-L-吡喃鼠李糖基)氧代]-,(3b)-(9CI) 鼠特灵 鼠尾草酸醌 鼠尾草酸 鼠尾草酚酮 鼠尾草苦内脂 黑蚁素 黑蔓醇酯B 黑蔓醇酯A 黑蔓酮酯D 黑海常春藤皂苷A1 黑檀醇 黑果茜草萜 B 黑五味子酸 黏黴酮 黏帚霉酸 黄黄质 黄钟花醌 黄质醛 黄褐毛忍冬皂苷A 黄蝉花素 黄蝉花定